Last reviewed · How we verify
Cell-culture rabies vaccine
Cell-culture rabies vaccine is a Inactivated viral vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Rabies post-exposure prophylaxis, Rabies pre-exposure prophylaxis. Also known as: VeroRab.
A cell-culture derived rabies vaccine that stimulates the immune system to produce antibodies and cellular immunity against rabies virus.
A cell-culture derived rabies vaccine that stimulates the immune system to produce antibodies and cellular immunity against rabies virus. Used for Rabies post-exposure prophylaxis, Rabies pre-exposure prophylaxis.
At a glance
| Generic name | Cell-culture rabies vaccine |
|---|---|
| Also known as | VeroRab |
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated viral vaccine |
| Target | Rabies virus glycoprotein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
Cell-culture rabies vaccines are produced by growing rabies virus in mammalian cell lines (such as Vero cells) rather than in animal neural tissue, then inactivating the virus. This approach generates a purified, safer immunogen that triggers both humoral (antibody) and cell-mediated immune responses to prevent rabies infection when administered post-exposure or pre-exposure.
Approved indications
- Rabies post-exposure prophylaxis
- Rabies pre-exposure prophylaxis
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Headache
- Myalgia
- Fever
- Nausea
Key clinical trials
- A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis. (PHASE3)
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults (PHASE1)
- Immunogenicity and Safety of a Purified Vero Rabies Vaccine (PHASE2)
- An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa (PHASE3)
- Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa (PHASE3)
- Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children (PHASE3)
- Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cell-culture rabies vaccine CI brief — competitive landscape report
- Cell-culture rabies vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Cell-culture rabies vaccine
What is Cell-culture rabies vaccine?
How does Cell-culture rabies vaccine work?
What is Cell-culture rabies vaccine used for?
Who makes Cell-culture rabies vaccine?
Is Cell-culture rabies vaccine also known as anything else?
What drug class is Cell-culture rabies vaccine in?
What development phase is Cell-culture rabies vaccine in?
What are the side effects of Cell-culture rabies vaccine?
What does Cell-culture rabies vaccine target?
Related
- Drug class: All Inactivated viral vaccine drugs
- Target: All drugs targeting Rabies virus glycoprotein
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Immunology
- Indication: Drugs for Rabies post-exposure prophylaxis
- Indication: Drugs for Rabies pre-exposure prophylaxis
- Also known as: VeroRab